Key weight loss results at 48 weeks by group: Response rates at 48 weeks (12 mg dose): 100% achieved greater than or equal to 5% weight loss 93% achieved greater than or equal to 10% weight loss 83% achieved greater than or equal to 15% weight loss The cardiometabolic improvements were also significant, with reductions in blood pressure, triglycerides, LDL cholesterol, HbA1c, fasting glucose, and fasting insulin across all dose groups
Clinical Study Results (TRIUMPH & TRANSCEND) Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors: Weight reduction: In phase 2 and phase 3 clinical studies, treated participants achieved approximately 24% to 28.7% weight loss over 4868 weeks
I.MorganD
Aithal 20 , Naaventhan Palaniyappan 21 , Daeho Lee 22 , Patrik Nasr 23 , Christophe Cassinotto 24 , Victor De Ledinghen 25 , Annalisa Berzigotti 26 , Yuly Paulin Mendoza 27 , Mazen Noureddin 28 , Emily Truong 29 , Jrme Boursier 30 , Marc De Saint Loup 31 , Masashi Hirooka 32 , Toshihide Shima 33 , Dr Shalimar 34 , Hannes Hagstrm 35 , Mattias Ekstedt 23 , Camilla Akbari 36 , Wah Kheong Chan 14 , Emmanuel A
Its formulated with Arginine and Hawthorn berry extract to promote circulation and normal blood pressure
Most GLP-1 medications start at a low dose and gradually increase every four weeks to minimize gastrointestinal side effects